ScripSan Francisco start-up 3T Biosciences came out of stealth mode on 25 August with $40m in new venture capital from a series A round led by Westlake Village BioPartners with participation from Lightsp
ScripTwo highly anticipated initial public offerings finally launched on 10 October and landed at the low end of their proposed IPO price ranges, but both BioNTech SE and Vir Biotechnology Inc. are amo
ScripInitial public offerings by biopharmaceutical companies in the US took a breather during the first two weeks of July as investors took time off around Independence Day, but drug developers – including
ScripThe progression of investigational products through a series of increasingly sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for commer